Yusimry
Adalimumab biosimilar developed by Coherus BioSciences, development code CHS-1420. Reference product Humira.
About Yusimry
Yusimry was developed by Coherus BioSciences and approved in the United States in 2021. It has not sought approval elsewhere and is not interchangeable. In 2024 Coherus sold the product, and the licence now sits with Emerge Bioscience. It was notable at launch for a low list price, part of a strategy to sell directly to large pharmacies and health plans.
Status by market
United States · Yusimry
US Food and Drug AdministrationApprovedEuropean Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Yusimry holds an approval, these are the other adalimumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| FDA | 9 | Alvotech (Simlandi / Hukyndra / Libmyris), Amgen (Amjevita / Amgevita), Boehringer Ingelheim (Cyltezo), Celltrion (Yuflyma), Fresenius Kabi (Idacio), Fujifilm Kyowa Kirin Biologics (Hulio), Pfizer (Abrilada / Amsparity), Samsung Bioepis (Hadlima / Imraldi), Sandoz (Hyrimoz / Hefiya) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Coherus BioSciences: Udenyca.
Chronology
- FDADec 2021Approved by FDA
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)
Planning adalimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant